Oncomine Acute Myeloid Leukemia AML Panel Test
Comprehensive Genetic Analysis for Acute Myeloid Leukemia
The Oncomine Acute Myeloid Leukemia AML Panel Test represents a breakthrough in precision oncology, offering comprehensive genetic profiling for patients with suspected or confirmed AML. This advanced next-generation sequencing (NGS) test analyzes over 60 key genetic mutations and fusion genes associated with Acute Myeloid Leukemia, providing clinicians with critical information for diagnosis, prognosis, and treatment selection.
What Does the Oncomine AML Panel Test Measure?
This sophisticated molecular diagnostic test detects and analyzes a comprehensive panel of genetic alterations including:
- Point Mutations: ABL1, ASXL1, BCOR, BAALC, CBL, CEBPA, DNMT3A, EZH2, ETV6, FLT3, GATA2, HRAS, IDH1, IDH2, IKZF1, JAK2, KIT, KRAS, MYD88, MYC, MECOM, NRAS, NPM1, NF1, PHF6, PPRF8, PTPN11, RUNX1, SF3B1, SRSF2, SMC1A, SH2B3, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2
- Fusion Genes: ABL1, BCL2, CCND1, CREBBP, ETV6, FGFR1, FGRF2, FUS, HMGA2, JAK2, KMT2A, MECOM, MLL, MYH11, MMLT3, MLLT10, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM15, RUNX1, TCF3
Who Should Consider This Test?
The Oncomine AML Panel Test is recommended for individuals experiencing:
- Unexplained fatigue, weakness, or pallor
- Frequent infections or fever without apparent cause
- Easy bruising or unusual bleeding
- Bone pain or tenderness
- Enlarged lymph nodes, spleen, or liver
- Unexplained weight loss or night sweats
- Abnormal blood counts detected during routine testing
- Patients with newly diagnosed AML for comprehensive genetic profiling
- Individuals with relapsed or refractory AML requiring alternative treatment options
Key Benefits of the Oncomine AML Panel Test
- Precision Diagnosis: Identifies specific genetic mutations driving AML development
- Personalized Treatment: Guides selection of targeted therapies based on genetic profile
- Prognostic Information: Helps predict disease course and treatment response
- Minimal Residual Disease Monitoring: Enables detection of low-level disease after treatment
- Comprehensive Analysis: Single test covers multiple genetic alterations instead of sequential testing
- Clinical Trial Eligibility: Identifies patients who may benefit from experimental therapies
Understanding Your Test Results
Your results will provide detailed information about detected genetic mutations and their clinical significance:
- FLT3 Mutations: May indicate need for FLT3 inhibitors like midostaurin
- IDH1/IDH2 Mutations: Potential candidates for IDH inhibitors such as ivosidenib or enasidenib
- NPM1 Mutations: Generally associated with favorable prognosis in absence of FLT3-ITD
- TP53 Mutations: Often indicate poor prognosis and may require aggressive treatment approaches
- Fusion Genes: Specific translocations may guide targeted therapy selection
Your hematologist or oncologist will interpret these results in the context of your overall clinical picture to develop the most effective treatment plan.
Test Pricing Information
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Oncomine Acute Myeloid Leukemia AML Panel Test | $1024 USD | $1138 USD |
Sample Requirements and Processing
Sample Type: 3 mL (2 mL min.) whole Blood OR Bone Marrow in 1 Lavender top (EDTA) tube. Ship refrigerated. DO NOT FREEZE.
Turnaround Time: Sample by 1st / 16th of every month; Report 15th / 30th of Same month
Pre-test Instructions: Duly filled NGS Test Requisition Form (Form 40) is mandatory.
Nationwide Availability
We have branches across the United States, serving patients in all major cities including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, Austin, Jacksonville, Fort Worth, Columbus, Charlotte, San Francisco, Indianapolis, Seattle, Denver, Washington DC, Boston, El Paso, Nashville, Detroit, Oklahoma City, Portland, Las Vegas, Memphis, Louisville, Baltimore, Milwaukee, Albuquerque, Tucson, Fresno, Sacramento, Kansas City, and Atlanta.
Book Your Test Today
Take control of your AML diagnosis and treatment journey with comprehensive genetic testing. Our expert team is ready to assist you with scheduling and answer any questions about the Oncomine AML Panel Test.
Call or WhatsApp: +1(267) 388-9828
Schedule your appointment today to receive the most advanced genetic analysis for Acute Myeloid Leukemia and unlock personalized treatment options based on your unique genetic profile.
